https://biotechmorning.com/news/shkreli-violates-lifetime-pharma-ban Biotech Morning en 2026-10-16T14:14:58.969Z Pharma's Most Infamous Bad Boy Can't Stop Breaking the Rules https://biotechmorning.com/news/pennsylvania-big-pharma-investment-merck-gsk Biotech Morning en 2026-10-16T14:14:18.386Z Pennsylvania Just Became Big Pharma's Favorite Zip Code https://biotechmorning.com/news/lilly-obesity-pill-european-hurdle Biotech Morning en 2026-10-16T14:13:29.749Z Lilly's Obesity Pill Just Cleared Its Biggest European Hurdle https://biotechmorning.com/news/biotech-seed-funding-drops-2026 Biotech Morning en 2026-10-16T14:12:39.526Z Biotech's Investor Class Is Ghosting Early-Stage Startups https://biotechmorning.com/news/china-biotech-export-controls-window-open Biotech Morning en 2026-10-16T14:11:59.404Z China Just Locked the Vault on Biotech Secrets (But Left a Window Open) https://biotechmorning.com/news/rnai-biggest-problem-200-million-bet-city-therapeutics Biotech Morning en 2026-10-16T14:11:16.955Z RNAi's Biggest Problem Just Got a $200 Million Bet https://biotechmorning.com/news/revita-device-glp1-weight-regain-remain1-results Biotech Morning en 2026-10-16T14:10:24.285Z The Device That Wants to Save You From Your GLP-1 Breakup https://biotechmorning.com/news/iambic-therapeutics-ipo-150-million Biotech Morning en 2026-10-15T14:14:43.430Z The AI Cancer Startup That Just Talked Wall Street Into $150 Million https://biotechmorning.com/news/ipf-claims-another-victim-syndax-stock Biotech Morning en 2026-10-15T14:13:56.057Z IPF Claims Another Victim (and Syndax's Stock Pays the Price) https://biotechmorning.com/news/astrazeneca-insitro-ai-mash-deal Biotech Morning en 2026-10-15T14:13:10.858Z AstraZeneca Just Bet $1.5 Billion That AI Can Crack the Liver https://biotechmorning.com/news/vertex-10-billion-crinetics-acquisition-5 Biotech Morning en 2026-10-15T14:12:19.049Z Vertex Just Dropped $10 Billion on a Company Most People Haven't Heard Of https://biotechmorning.com/news/agilent-proscia-240m-digital-pathology-acquisition Biotech Morning en 2026-10-15T14:11:39.314Z Agilent Just Paid $240M for a Company That Started in a Dorm Room https://biotechmorning.com/news/fda-rare-disease-framework-overhaul Biotech Morning en 2026-10-15T14:10:50.550Z The FDA Just Admitted Its Rare Disease Playbook Is Broken https://biotechmorning.com/news/mit-in-vivo-nk-cell-reprogramming-nanoparticles Biotech Morning en 2026-10-15T14:10:02.844Z What If You Could Skip the Factory and Build Cancer-Killing Cells Inside the Body? https://biotechmorning.com/news/arrowhead-aro-mapt-tau-rna-alzheimers Biotech Morning en 2026-10-15T14:09:21.035Z Arrowhead Found a Way to Quiet the Brain's Most Toxic Protein https://biotechmorning.com/news/omass-therapeutics-310-million-series-c Biotech Morning en 2026-10-15T14:08:32.038Z Britain's Bid to Build a Biotech Giant Just Got $310 Million Louder https://biotechmorning.com/news/anktiva-bladder-cancer-label-expansion Biotech Morning en 2026-10-15T14:07:44.787Z The Bladder Cancer Drug That Just Got a Bigger Playground https://biotechmorning.com/news/legend-biotech-in-vivo-car-t-lb2501 Biotech Morning en 2026-10-15T14:07:03.420Z What If Your Body Could Build Its Own Cancer-Killing Cells?